San Antonio, Texas 78229


Purpose:

Patients with invasive bladder cancer will be given 3-6 treatments (based on treatment response) BCG intravesically followed by a cystectomy.


Study summary:

Patients with muscle invasive (≥T1) bladder cancer will be given 3-6 treatments (based on treatment response) intravesical TICE® BCG. BCG is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis. After completion of BCG treatments the patient will undergo a cystectomy. A portion of bladder tumor tissue and lymph nodes will be collected for research purposes during the cystectomy.


Criteria:

Inclusion Criteria: 1. Have suspected or known invasive (≥T1) bladder cancer 2. Be able to give informed consent 3. Be age 18 or older 4. Not be in an immunosuppressed state (e.g. HIV+, use of chronic steroids >1 month) Exclusion Criteria: 1. Have non-invasive (<T1) bladder cancer 2. Unable to give informed consent 3. < 18 or older 4. Is in an immunosuppressed state (e.g. HIV+, use of chronic steroids >1 month)


NCT ID:

NCT02365207


Primary Contact:

Principal Investigator
Robert Svatek, MD
University of Texas

Robert Svatek, MD
Phone: 210-567-5676
Email: svatek@uthscsa.edu


Backup Contact:

Email: kendrick@uthscsa.edu
Kerri Kendrick, PA-C
Phone: 210-567-5676


Location Contact:

San Antonio, Texas 78229
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 19, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.